The stock of Organovo Holdings (NAS:ONVO, 30-year Financials) appears to be possible value trap, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line,

Catherine Wood (Trades, Portfolio)'s ARK Investment Management has revealed a large reduction in the Organovo Holdings Inc. (ONVO) position alongside a small reduction in the Syros Pharmaceuticals Inc. (SYRS) position according to GuruFocus' Real-Time Picks, a Premium feature.

ARK Investment Management combines a top-down and bottom-up approach in an attempt to identify innovation in the market early that can cause rapid cost decline. This allows them to capitalize on opportunities and provide long-term value to investors.

The firm's Organovo holding was acquired in 2016 and has grown over the last several

Catherine Wood (Trades, Portfolio) has become a leading figure in the financial media over the last couple of years thanks to the success of her investment firm, ARK Investment Management. The firm has launched five exchange-traded funds, all of which are dedicated to "disruptive innovation" of one form or another. ARK has beaten the wider stock market handily in recent years, a fact that has not gone unnoticed by investors, who poured more money than ever into its ETFs.

Unfortunately, a flood of capital into

Some analysts cite Hillary Clinton’s continued criticism of drug prices as a cause for a slump in biotech during the U.S. presidential campaign, but with the election behind us, many biotech enterprises saw at least a 9% increase due to Donald Trump’s victory.

Two companies in the biotech space entering the first quarter of 2017 may be in a position for their products, as well as stock prices, to move to greater heights, BioVie Inc. (BIVI) and Organovo Holdings Inc. (ONVO).

Organovo is a microcap biotech that produces a 3D-printed model using human liver cells that can be used in

What once took weeks to produce with pinpoint accuracy now boils down to hours under a printing platform. This new style of what has become known as additive manufacturing is creating entirely new ways of generating nearly anything. This has impacted a multitude of industries as well as industrialized countries to break into new manufacturing methods in the 21st century.

Take, for instance, Heritage Printing Technology (HAGE). Just last week, the company announced a major China-based distributor, Synergy Tech Co., will enhance the company’s exposure in one of the more prominent arenas for 3-D printing. Being that Synergy is based

The biotechnology and pharma sector has been one of the most stable segments in the stock market for the last few years. The growth of this industry can be seen from the fact that the Nasdaq Biotechnology Index and S&P 500 Biotechnology Index grew by a whopping 36.9% and 43.6% respectively in 2014. The following chart shows the comparison of these indices with the Dow Jones Industrial Average (6.1%).

Though there were many pharmaceutical giants that grew manifold over the years, when it comes to buying options, certain stocks have clearly stood out from the rest.

Organovo (ONVO) investors have been restlessly anticipating the launch of the organization's 3-D liver measures, its first genuine item. Anyhow that won't happen until the end of this current year – and we won't know the amount of revenue it delivers until mid-2015.

Living up to the expectations

Researchers with Roche (RHHBY) were a percentage of the first experts to get involved in Organovo's 3-D liver measures. What they discovered impressed them: Organovo's liver cells reacted in ways that just the local liver has possessed the capacity to show as such.

Roche took a known poison and acquainted it with

Organovo (ONVO) investors have been restlessly anticipating the launch of the organization's 3-D liver measures its first genuine item. Anyhow that won't happen until the end of this current year –Â and we won't know the amount of revenue it delivers until mid-2015.

Living up to the expectations

Researchers with Roche (RHHBY) were a percentage of the first experts to get involved in Organovo's 3-D liver measures. What they discovered impressed them: Organovo's liver cells reacted in ways that just the local liver has possessed the capacity to show as such.

Roche took a known poison and acquainted it with

Added substance assembling, or 3D printing, is getting a ton of consideration recently. Analysts expect the likes of 3D Systems (DDD) and Stratasys to produce solid earnings development in the following couple of years as the applications of 3D printing increase. Nonetheless, one organization that is truly making an imprint with 3D printing innovation is Organovo (ONVO).

Colossal potential

It is accepted that one day, Organovo would have the capacity to print human organs that will then be used in transplants. Investors have perceived the organization's potential and it has picked up an impressive 112% this year. Notwithstanding, assembling

Shares of almost all 3D printing companies have appreciated considerably this year. Even though analysts are expecting 3D printing to be worth more than $5 billion by 2018, I don't think investing in 3D printing companies, mainly 3D Systems (DDD), is a good idea. Investors have bid up 3D printing stocks in the hope that its technology will revolutionize the industrial manufacturing process and it will also have a massive presence in the consumer segment. However, given the flaws of the technology, I think investors would be better off shorting 3D printing stocks like 3D Systems, Stratasys (SSYS), Voxeljet (VJET),

The hype surrounding the 3D printing industry is huge, with many analysts claiming that this technology will grow into the next-generation technology for industrial manufacturing and production. I, for one, don't believe that this hype is justified and I remain highly skeptical of 3D printing's future.

There are numerous companies that are involved in this industry, which makes growth for any single company even more difficult. In addition, the arrival of new companies like Voxeljet (NYSE: VJET) will intensify competition further. 3D Systems (NYSE: DDD), due to its diversified product portfolio and wide distribution network, is often projected to become

It doesn't take a genius to point out that all 3D printing companies are overvalued and Organovo is no exception to it. However, while shares of 3D Systems have appreciated because of hype and unrealistic expectations, Organovo has grown primarily due to increase in institutional ownership. Therefore, even though it is overpriced, I think investors should consider buying it as its value may not come down because of higher institutional ownership.

Moreover, since Organovo has embarked upon a completely different approach to 3D printing, it doesn't have to face stiff competition. By comparison, 3D Systems will have to compete against